Overview

OLE of Phase 2b/3 Study ANAVEX2-73-AD-004

Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2b/3 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and effficacy of daily treatment.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Anavex Life Sciences Corp.
Collaborators:
Anavex Australia Pty Ltd.
Anavex Germany GmbH